Ipilimumab Approval Highlights Active Immunotherapy
Renaissance
25 March 2011
Life Science Digest
On Friday, March 25, 2011, the U.S. Food and Drug Administration
(FDA) approved Yervoy® [ipilimumab] by Bristol-Myers
Squibb for the treatment of patients with late-stage
melanoma.
Approval of ipilimumab is the second victory for the field of
active immunotherapy in oncology within a year. On
April 29, 2010, the FDA approved the very first active
immunotherapy for the treatment of cancer - Dendreon
Corporation's Provenge® for metastatic castrate-resistant
prostate cancer. The fact that two active immunotherapies
have demonstrated improved survival in randomized Phase 3 trials
and subsequently been approved by the FDA has reignited enthusiasm
for the field of active immunotherapy, which has experienced nearly
a dozen failures in Phase 3 clinical trials.
Full article
DISCLAIMER
The links and content above are provided for your convenience to provide further information and do not constitute an endorsement by Bavarian Nordic. We have no control over the nature, content and availability of the sites that are being linked to and thus we assume no responsibility for the privacy practices on such websites.
